Domestic cats share human living environment and genetic traits. They develop spontaneous feline mammary carcinoma (FMC) with similar histopathology as human breast cancer. HER2 and AKT phosphorylation was demonstrated in primary FMC by immunoblot, indicating HER2 as a therapeutic target. FMC lines K12 and K248 expressing HER1, HER2 and HER3 were sensitive to receptor tyrosine kinase (RTK) inhibitors gefitinib and lapatinib. To test HER2 vaccine response in cats, purpose-bred, healthy cats were electrovaccinated with heterologous (xenogeneic) or point-mutated feline HER2 DNA. T-cell reactivity to feline self-HER2 was detected in 4 of 10 cats that received bear HER2, human/rat fusion HER2 (E2Neu) or mutant feline HER2 (feHER2-K) which contains a single amino acid substitution. The variable T-cell responses may resemble that in the genetically heterogeneous human population. All immune sera to heterologous HER2 recognized feline HER2 expressed in 3T3 cells (3T3/HER2), but not that in FMC K12 or K248. Immune sera to mutant pfeHER2-K bound 3T3/HER2 cells weakly, but they demonstrated better recognition of K12 and K248 cells that also express HER1 and HER3, suggesting distinct HER2 epitopes displayed by FMC that may be simulated by feHER2-K. In summary, HER2 DNA electroporation overcomes T-cell immune tolerance in ~40% healthy cats and induces antibodies with distinct specificity. Vaccination studies in domestic cats can expedite vaccine iteration to guide human vaccine design and better predict outcome, with the added benefit of helping feline mammary tumor patients.
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Introduction
Cancer vaccines hold great promise in disease treatment and prevention. However the prolonged and costly process of regulatory approval, GMP production and clinical trials prohibits efficient iteration between novel lab findings and human clinical trials. Test systems that can predict human immune responses will expedite vaccine development and cancer immunotherapy. Although murine models have been enormously successful in revealing basic immunology and providing proof of concept, they may fall short in predicting how the heterogeneous human population would respond to cancer vaccines (1) (2) (3) . Transgenic mice expressing human tumor-associated antigens (TAA) and developing spontaneous tumors have produced more relevant results (2, 4, 5) . We showed a striking difference in HER2 DNA vaccine response between BALB/c and C57BL/6 HER2 transgenic mice, illustrating the impact of genetic background on vaccine responses (6) . Since a syngeneic mouse strain represents a single individual, each new vaccine should ideally be tested in multiple mouse strains representing diversified genetic backgrounds.
In transgenic mice, exogenous promoters are often used to drive the expression of TAAs and antigenic peptides are usually presented by mouse rather than human major histocompatibility complex (MHC). T-cell repertoires are selected in the thymus where both mouse and transgenic human antigens are presented, confounding the test system. The short life spans, lack of natural tumorigenesis and comparatively small body weights are amongst the incongruities between rodents and humans. The limitations of these models bring clarity to the need for intermediate animal systems that more closely resemble that in humans, have similar cancer etiology, express a comparable repertoire of TAAs and respond to the vaccine delivery approaches similar to humans. Importantly, immune responses in a genetically diverse outbred population would predict more accurately the range of immune responses in humans.
The domestic cat population is estimated at 1 billion worldwide (7) with approximately 95 million residing in US households (8). Feline whole genome sequencing and single nucleotide polymorphism maps have been generated (7, 9) , revealing homologous genetic diseases between humans and cats (10) . Pet animals share human dwellings and develop cancers similar to that in humans. Both domestic dogs and cats develop spontaneous mammary tumors.
The incidence of mammary tumor is higher in dogs (11, 12) , but half of canine mammary tumors are benign, while 90% of feline mammary tumors are malignant and mostly adenocarcinomas (13) (14) (15) . Hormonal regulation of canine and feline mammary tumors is evident because the incidence is drastically reduced by ovariohysterectomy (12, 16) . About 15% of non-spayed domestic cats develop spontaneous mammary carcinoma with disease progression and histopathology similar to that of human breast cancer, and HER2 expression has been reported (14, (17) (18) (19) (20) (21) (22) (23) (24) . Feline mammary carcinoma patients are treated with surgery, radiation and chemotherapy. Taken together, domestic felines represent a particularly suitable model for evaluating breast cancer vaccines.
DNA vaccines have advanced more expediently in veterinary than in human medicine.
The first approved therapeutic cancer vaccine in any species was a plasmid DNA encoding heterologous (xenogeneic) human tyrosinase for treating canine oral melanoma (14, 25, 26) .
Two other DNA vaccines targeting West Nile virus in horses (27) and hematopoietic necrosis virus in salmon (28) have also been approved for veterinary use. In this study, intramuscular electrovaccination was used to evaluate novel feline HER2 DNA vaccines because the procedure is well tolerated by humans (29, 30) and gene expression is dramatically enhanced by electroporation (29, (31) (32) (33) (34) .
HER2 DNA vaccines that we developed have been tested in human clinical trials, in which a kinase-deficient full length human HER2 DNA induced T-cell responses in breast cancer patients (35) (36) (37) . We reported another HER2 construct expressing the wild-type (WT) human extracellular and transmembrane domains (36, 37) , which was also tested in breast cancer patients, but without evidence of T-cell responses (38) . A human HER2/rat neu hybrid vaccine showed improved efficacy in transgenic mice (4, 39) and a trial is currently open for Culture Collection. MCF7 cells were obtained from Lisa Polin of the Karmanos Cancer Institute.
All cells were maintained in Dulbecco's Modified Eagle's Medium supplemented with fetal bovine sera, penicillin and streptomycin. The feline origin of K248 and K12 cells has been authenticated by short tandem repeat (STR) analysis of four loci (Supplemental Figure 1) .
Immunohistochemical analysis
Pathologic diagnoses were performed according to the WHO classification for tumors in domestic animals. For feline HER2 detection, epitopes were retrieved with sodium citrate buffer (pH 6.0) and histological-grade primary antibodies were applied according to manufacturer's recommendation (HER2, clone Z4881, Invitrogen) followed by broad-spectrum HRP polymer conjugate (SuperPicTure™ Polymer Detection Kit, Zymed) and DAB substrate (Pierce Biotech).
Feline mammary tumor cells, K248, were injected subcutaneously into SCID mice. Tumor explants were used as controls.
DNA cloning and construction
All cloning primer sequences are shown in Supplementary Table 2. Feline HER2 (ERBB2) cDNA was cloned from cell lines K248 (40) and K12 (41) , and from the ovary of a domestic shorthair cat using a Protoscript kit (New England Biolabs), all of which showed identical sequences. The confirmed full-length feline ERBB2 (feHER2) cDNA sequence has been submitted to Genbank (#JN990983). For vaccination, a stop codon was introduced after codon 687 to delete the oncogenic intracellular domain, then subcloned into pVax1; the resultant pfeHER2 contains the signal peptide, and the extracellular and transmembrane domains of feline HER2. The pfeHER2-K contains a single nucleotide substitution in codon 141 (cag -> aag) of the extracellular domain I, based on our reported sequence of feline ERBB2 (Genbank JN990983) and was generated by PCR-based methods and verified by DNA sequencing.
Black bear HER2 cDNA was similarly cloned from the liver tissue of a black bear. The cDNA sequence was submitted to Genbank (#JQ040508). DNA vaccine pbearHER2 encoding the signal peptide and the extracellular and transmembrane domains was constructed by PCRbased methods similar to that described for pfeHER2.
Feline GM-CSF cDNA was amplified from a randomly-primed cDNA library (Protoscript, New England Biolabs) prepared from ConA-stimulated feline peripheral blood mononuclear cells (PBMC) and cloned into pcDNA3.1. The open reading frame sequence was in accord with the consensus of feline CSF2 cDNAs in Genbank (AY878357, NM001009840, AF053007 and AF138140).
Generation of recombinant feline HER2 and human Fc fusion protein -feHER2-Fc
A plasmid encoding the secreted fusion protein of feline HER2 extracellular domain fused to human Ig Fc was constructed. Feline HER2 cDNA and the human Ig Fc domain were PCR amplified and fused by overlap-extension priming, giving a 2680 bp product, which was cloned into the HindIII and XbaI sites of pVax1. Murine 3T3 cells were transfected with this construct and the feHER2-Fc protein in culture supernatant was quantified by ELISA using mouse anti-human HER2 capture mAb (clone TA-1, Calbiochem), which cross-reacts with feline HER2. Rabbit anti-human IgG was the detection antibody (Jackson Immuno). huHER2-Fc was purchased from Sino Biologicals.
Electrovaccination of mice and cats
Mice were injected with an admix of 50 μg each of vaccine plasmid and plasmid encoding murine GM-CSF (pmuGM-CSF) in 50 μl PBS in the gastrocnemius muscle (42) .
Conductive gel was applied on the skin over the injection sites. Electroporation was conducted with NEPA21 electroporator (Napagene) using a tweezer electrode. Three 50 msec degenerating bipolar pulses of 100 V were administered at each site. Cats were injected with 1.5 mg each of HER2 vaccine plasmid and pfeGM-CSF in 1.5 mL PBS, divided equally over three injection sites in the biceps femoris or quadriceps. Two rounds of electroporation were applied to each site as described using a 1.5 cm 2 caliper electrode (BTX).
Cell proliferation assay
Cells were plated at 2-5,000/well in 96-well plates and treated with gefitinib or lapatinib in quintuplicate for 48 h. Alamar Blue reagent (Life Technologies) was added and fluorescence measured after 3-4 h. The % proliferative activity was determined relative to the average of untreated samples.
Western blot analysis
Cells or tissues were lysed in a non-ionic detergent lysis buffer (43) To measure antibody level in immune sera, mouse or feline sera were incubated with 3T3 cells engineered to express the designated antigen and detected by PE-conjugated antimouse or feline IgG secondary antibody (SantaCruz). Mouse antibody concentrations were extrapolated from a standard curve of HER2 mAb TA-1. Feline antibody titers were determined by serial dilution until binding was no longer detected above that of the isotype control.
Analysis of T-cell response by ELISPOT
Mouse splenocytes or feline PBMCs isolated by ficoll separation (GE Healthcare) were maintained in Roswell Park Memorial Institute medium supplemented with fetal bovine sera, penicillin/streptomycin. Feline PBMCs were supplemented with 0.5 ng/mL feline IL2 (R&D Systems). Cells were plated at 2x10 5 /well in round bottom 96-well plates and cultured with 10 μg/mL feHER2Fc (3T3 supernatant-equivalent as described above), huHER2Fc, human IgG control (Jackson Immunolabs) or control 3T3-conditioned medium for 48 (mouse) or 72 (feline) hours. Total well contents were then transferred to mouse or feline (R&D Systems) IFNγ ELISPOT plates and incubated for an additional 48 hours prior to detection and enumeration as previously described (44) or per manufacturer protocol. Visualized cytokine spots were enumerated using the ImmunoSpot analyzer (CTL, Shaker Heights, OH) and expressed as the number of cytokine-producing cells per 10 6 splenocytes or PBMCs.
Results

Expression of HER2 in feline mammary carcinoma (FMC)
Expression of ERBB family receptor tyrosine kinase (RTK) in FMC was measured by flow cytometry. Surface staining of HER1 (EGFR), HER2 and HER3 was detected in K12 and K248 cells using mAbs to their human homologs ( Figure 1A ). MHC I expression was also detected with mAb W6/32 to a constant region of human MHC I. Control human ovarian cancer cell line SKOV3 showed elevated HER1 and HER2, while lacking HER3 expression (45) . Feline HER2 expression in primary FMC clinical samples (Supplemental Table 1 We previously showed that heterologous rat neu electrovaccination overcame T-cell tolerance in human HER2 transgenic (Tg) mice, but immune sera to neu did not recognize human HER2 (41) . A human HER2-rat neu hybrid vaccine (pE2Neu) containing human ERBB2 
extracellular domains (ECD) 1/2, rat neu ECD 3/4 and neu transmembrane domain induced both humoral and cellular immunity in HER2 Tg mice (4) . Based on these findings, heterologous bear, human and rat ERBB2 genes sharing high levels of sequence identity with feline ERBB2, and were tested as candidate vaccines. To evaluate if minimal alteration could be engineered to afford immunogenicity while preserving feline HER2 epitopes, a single amino acid, glutamine-141 in domain 1 of the feline HER2 ECD, was replaced with lysine to generate feHER2-K.
Supplemental Figure 4A /B show the predicted 3D structure of feHER2-K domains I-III using cartoon and space-filling models. The predicted effect of substituting Q with K at a.a. 141 is portrayed by an electrostatic surface model (SYBYL-X 2.1.1 software; Tripos), where the electropositive side chain of K is indicated by red and Q is shown in blue (Supplemental Figure   4C ). The Q141K substitution appears to create only subtle changes which did not alter the immune response to the dominant foreign epitopes. Modest cross-reactivity between feline and human HER2 immune sera was also observed. Neither pre-nor post-vaccination mouse serum bound un-transfected 3T3 cells (Supplemental Figure 5B) , supporting the HER2 specificity of the immune sera.
Immunogenicity of feHER2-K
To measure T-cell response, a feline HER2 extracellular domain (ECD) and human Ig Fc fusion protein, feHER2-Fc, was generated as the test antigen and verified by Western blot 
DNA electrovaccination of cats
For feline vaccinations, GM-CSF cDNA was cloned from feline PBMCs (pfeGM-CSF).
Generation of recombinant GM-CSF in the supernatant of transfected 3T3 cells was verified by
Western blot (R&D Systems, Inc, data not shown). The feasibility of DNA electrovaccination in cats was initially tested with pE2Neu encoding a fusion protein of HER2 and neu (4). Three healthy purpose-bred, pathogen-free domestic shorthair cats 12-24 months of age were injected Figure 6A) .
Immune response to novel HER2 DNA vaccines
A panel of HER2 vaccines was tested in fifteen additional healthy cats between 5-8 months of age. Cats were electrovaccinated 4x with pfeHER2, pfeHER2-K, pbearHER2, pE2Neu, or an admix vaccine of pfeHER2-K and pE2Neu. As observed previously, the six cats that received pE2Neu either alone or in combination with pfeHER2-K developed high levels of IgG antibody to human HER2 peaking after three vaccinations ( Figure 5B IFNγ T-cell response to feHER2-Fc was measured to evaluate reactivity to self-HER2 Figure 6B ). Of the 10 cats evaluated, three produced significant feHER2-specific T-cell responses, with one cat each from the pfeHER2-K (~100 SFU per million cells), pE2Neu (~270 IFNγ spots) and pbearHER2 (~280 IFNγ spots) groups. The observed T-cell responses indicate the immunogenic nature of both heterologous and point-mutated HER2 vaccine. The 30% response rate may reflect the heterogeneous genetic background of outbred cats, as in humans.
Three bi-weekly booster vaccinations were given to five cats that received pfeHER2-K or pfeHER2-K+pE2Neu ( Figure 6C ). Only 1 of the 3 cats receiving the admixed vaccine converted from a non-responder to a responder after three boosters (~135 SFU/10 6 PBMCs). Therefore, a total of 40% T-cell response rate to self-HER2 was achieved in healthy cats. Those cats initially receiving pE2Neu or pbearHER2 were boosted 3x with pfeHER2-K ( Figure 6D /E). Responses to recombinant human or feline HER2 did not increase, suggesting that cross-reactive T cells, not common epitopes in HER2 from pE2Neu or bear HER2, contributed to feline HER2 reactivity.
The cats tolerated the vaccination procedure without signs of pain or discomfort after recovery from anesthesia. No adverse side effects were detected 6-12 months after the final vaccination and the cats continue to thrive.
Discussion
To the best of our knowledge, this is the first report of cats receiving DNA 
immunization modality. In 2/5 healthy cats, vaccination with pE2Neu or pbearHER2 overcame immune tolerance to trigger T-cell responses to self-feHER2. Vaccination with pfeHER2-K also induced feHER2-specific T-cell responses in 1 of 3 cats. Additional studies will be necessary to validate and enhance T-cell activation by feline HER2 vaccines. Antibody binding to 3T3/feHER2 was detected in cats vaccinated with heterologous HER2. Although pfeHER2-K immune sera were the least effective in binding 3T3/feHER2, these immune sera recognized unique epitopes on FMC K12 and K248. Taken together, outbred cats represent a new model system for evaluating novel HER2 DNA vaccines. Importantly, the vaccine design and feline test system can be extrapolated to other tumor-associated self-antigens to expedite the development of veterinary and human cancer vaccines.
feHER2-K immune sera appear to bind epitopes on 3T3/feHER2-K as well as on K12 and K248 FMC, but only minimally to 3T3/feHER2. Although other interpretations may exist, we propose the following scenario: feHER2-K recapitulates a cryptic HER2 epitope naturally displayed when WT feHER2 is heterodimerized or associated with other ERBB family members.
Cats immunized with heterologous pE2Neu or pbearHER2 produced antibodies that recognize dominant epitopes on WT feHER2 as well as feHER2-K expressed on 3T3 cells, but not the cryptic epitope exhibited by K12 or K248 cells. This seemingly subtle, but potentially critical difference in HER2 epitope recognition was made possible by vaccinating genetically unmanipulated cats that naturally express HER1, HER2, and HER3. It will be important to further evaluate immune sera from feline HER2 vaccines to better define the epitopes they recognize and those epitopes important for controlling signaling and tumor growth. Rationally designed HER2 DNA vaccines, engineered with modifications to specific domains, may help bring clarity.
Our previous study showed consistent responses to HER2 DNA electrovaccination in BALB/c HER2 Tg mice, but poor responses in C57BL/6 HER2 Tg mice (4, 42) 
